Striatonigral Degeneration Clinical Presentation

  • Author: Arif I Dalvi, MD; Chief Editor: Selim R Benbadis, MD   more...
 
Updated: Apr 13, 2012
 

History

Parkinsonism

The vast majority of patients with multiple system atrophy develop parkinsonism at some point, and the condition is often rapidly progressive.

Bradykinesia with rigidity, tremor, or postural instability is seen. Although the presentation can be asymmetrical (as is usually the case in Parkinson disease), symmetry of onset is particularly suggestive of multiple system atrophy with predominantly parkinsonian features (MSA-P). Absence of tremor is also suggestive of MSA-P (vs Parkinson disease). When present, tremor is usually irregular, postural, and may be associated with myoclonus. While resting tremor can be observed, it is uncommon.

Multiple system atrophy patients with parkinsonism may have a limited response to a trial of levodopa. However, a clear-cut response that is sustained beyond 2 years is unusual.

Dysautonomia

Some degree of autonomic failure is almost universal and may be the presenting symptom. Genitourinary complaints are common early in the disease. Symptoms include the following:

  • Male erectile dysfunction
  • Urinary symptoms - Frequency, urgency, incomplete bladder emptying, and incontinence
  • Postural or postprandial hypotension - Syncopal events may occur secondary to cerebral hypoperfusion

Sleep disturbances

When possible, obtain information on the patient’s history from the patient’s sleeping partner. Sleep-related symptoms include the following:

  • Rapid eye movement (REM) sleep behavior disorder
  • Obstructive symptoms - Snoring, stridor, obstructive apneas
  • Central symptoms - Central apneas, dysrhythmic breathing patterns
  • Insomnia and/or excessive daytime sleepiness
  • Restless legs syndrome

Additional findings

Additional findings in MSA-P include the following:

  • Cerebellar findings - Gait or limb ataxia, cerebellar dysarthria
  • Affective disorders - Depression, emotional lability
  • Cognitive impairment - difficulty with visuospatial tasks, decreased verbal fluency, diminished executive function skills
  • Dysphagia and/or dysphonia

Other etiologies

Features that suggest an etiology other than multiple system atrophy include the following:

  • Family history - Multiple system atrophy is a sporadic neurodegenerative disease; however, Machado-Joseph disease (SCA-3) can present with similar clinical features and has a genetic basis
  • Dementia - Cognitive deficits are sometimes present in multiple system atrophy, but dementia is not a predominant feature, unlike with diffuse Lewy body disease
  • Presence of hallucinations (not secondary to medication) - This suggests Lewy body disease[11]
Next

Physical Examination

Parkinsonism

Bradykinesia with rigidity, tremor, or postural instability occurs. Symmetrical onset is suggestive of multiple system atrophy (vs Parkinson disease). Absence of tremor is suggestive of MSA-P (vs Parkinson disease). When present, tremor is usually irregular, postural, and is associated with myoclonus. While resting tremor can be observed, it is uncommon.

Dysautonomia

Symptoms of dysautonomia include the following:

  • Urinary retention, elevated postvoid residual
  • Orthostatic hypotension - Systolic blood pressure reduction of more than 30 mm Hg or diastolic blood pressure reduction of more than 15 mm Hg within 3 minutes of standing from a previous period of recumbency of greater than 3 minutes

Cerebellar findings

Cerebellar findings include the following:

  • Gait or limb ataxia
  • Cerebellar dysarthria
  • Cerebellar oculomotor dysfunction - This may include saccadic pursuit movements, gaze-evoked nystagmus, and ocular dysmetria

Cognitive impairment

Although dementia (as a predominant feature) is a criterion for exclusion of multiple system atrophy, studies suggest that some degree of cognitive impairment is common in multiple system atrophy, and particularly so in MSA-P.[12] The extent of impairment varies significantly. When present, deficits include the following:

  • Visuospatial and constructional dysfunction
  • Impaired verbal fluency
  • Dysexecutive syndrome

Additional findings

Additional findings in MSA-P include the following:

  • Dysphagia and/or dysphonia
  • Stridor - Initially, stridor occurs during sleep, but later in the course of the disease it may occur during wakefulness
  • Corticospinal findings - Hyperreflexia or extensor plantar response is often present
  • Raynaud phenomenon, or "cold hands sign" - Cold, dusky, violaceous hands with poor circulatory return after blanching pressure[13]
  • Affective disorders - Depression, emotional lability

Other etiologies

Features that suggest an etiology other than multiple system atrophy include the following:

  • Classic pill-rolling tremor - Suggests Parkinson disease
  • Significant slowing of vertical saccades or vertical supranuclear gaze palsy - A sign of progressive supranuclear palsy
  • Dementia - Cognitive deficits are sometimes present in multiple system atrophy, but dementia is not a predominant feature
  • Presence of hallucinations (not secondary to medication) - Suggests Lewy body disease[11]
Previous
 
 
Contributor Information and Disclosures
Author

Arif I Dalvi, MD  Director, Movement Disorders Center, NorthShore University HealthSystem, Clinical Associate Professor of Neurology, University of Chicago Pritzker Medical School

Arif I Dalvi, MD is a member of the following medical societies: European Neurological Society and Movement Disorders Society

Disclosure: Nothing to disclose.

Coauthor(s)

Paula K Rauschkolb, DO  Staff Physician, Department of Neurology, Dartmouth-Hitchcock Medical Center

Paula K Rauschkolb, DO is a member of the following medical societies: American Academy of Neurology and American Medical Association

Disclosure: Nothing to disclose.

Stephen A Berman, MD, PhD, MBA  Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Additional Contributors

Maritza Arroyo-Muñiz, MD Associate Program Director, Professor of Neurology, Department of Neurology, University of Puerto Rico

Maritza Arroyo-Muñiz, MD is a member of the following medical societies: American Academy of Neurology, National Stroke Association

Disclosure: Nothing to disclose.

Syed T Arshad, MD Staff Physician, Department of Neurology, Dartmouth Hitchcock Medical Center

Syed T Arshad, MD is a member of the following medical societies: American Academy of Family Physicians, American Medical Association

Disclosure: Nothing to disclose.

Nestor Galvez-Jimenez, MD, MSc, MHA Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, and Movement Disorders Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. Feb 1 1999;163(1):94-8. [Medline].

  2. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. Aug 26 2008;71(9):670-6. [Medline].

  3. Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol. Feb 2012;38(1):4-24. [Medline].

  4. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord. Sep 2003;18 Suppl 6:S2-12. [Medline].

  5. Nagaishi M, Yokoo H, Nakazato Y. Tau-positive glial cytoplasmic granules in multiple system atrophy. Neuropathology. Jun 2011;31(3):299-305. [Medline].

  6. Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology. Jul-Aug 2004;23(4):201-8. [Medline].

  7. Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm. Dec 2005;112(12):1605-12. [Medline].

  8. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord. Jan 30 2008;23(2):294-6. [Medline].

  9. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. May 2008;131:1362-72. [Medline].

  10. Blumin JH, Berke GS. Bilateral vocal fold paresis and multiple system atrophy. Arch Otolaryngol Head Neck Surg. Dec 2002;128(12):1404-7. [Medline].

  11. Camacho V, Marquié M, Lleó A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies. Q J Nucl Med Mol Imaging. Aug 2011;55(4):476-83. [Medline].

  12. Kawai Y, Suenaga M, Takeda A, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology. Apr 15 2008;70(16 Pt 2):1390-6. [Medline].

  13. Klein C, Brown R, Wenning G, Quinn N. The "cold hands sign" in multiple system atrophy. Mov Disord. Jul 1997;12(4):514-8. [Medline].

  14. Pellecchia MT, Pivonello R, Colao A, Barone P. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. Clin Med Res. Dec 2006;4(4):322-5. [Medline].

  15. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet. Jun 28 1997;349(9069):1877-81. [Medline].

  16. Santamaria J, Iranzo A. Multiple System Atrophy and Sleep. Sleep Med Clin. 2008;3:337-345.

  17. Yoshida M. Multiple system atrophy -synuclein and neuronal degeneration. Rinsho Shinkeigaku. Nov 2011;51(11):838-42. [Medline].

  18. Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg. Dec 2011;113(10):823-9. [Medline].

  19. Massimo G, Limbucci N, Catalucci A, Massimo C. Neurodegenerative Diseases. Radiol Clin N Am. 2008;46:799-817.

  20. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. Nov 2002;73(5):517-23. [Medline].

  21. Hauser RA, Grosset DG. [(123) I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes. J Neuroimaging. Mar 16 2011;[Medline].

  22. Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. J Neurosurg. Mar 2004;100(3):553-6. [Medline].

  23. Talmant V, Esposito P, Stilhart B, Mohr M, Tranchant C. [Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Rev Neurol (Paris). Mar 2006;162(3):363-70. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.